Activating SCN1A to Treat Dravet Syndrome

Video

Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the company’s gene therapy pipeline, including their lead program ETX101.

“We are creating precision gene therapies capable of targeting disease mechanisms by replacing a gene, silencing gene expression, or creating patterns of gene expression through gene regulation. Our platform has huge potential because pediatric neurological disorders represent a significant proportion of the Global Burden of Disease because they contribute to premature mortality and years lived with disability.”

Encoded Therapeutics is tackling Dravet syndrome (DS) with their lead program, ETX101, which is designed to upregulate patients’ SCN1A gene, and therefore sodium channels within GABAergic inhibitory neurons, to reduce seizures and extend survival.

The company has been conducting the ENVISION study (NCT04537832) to further understanding of the natural history and disease course of DS to better develop therapies to treat it. The first participant was enrolled in the study in April 2021 and the study, which plans to enroll around 50 children, will be completed in June 2024.

GeneTherapyLive spoke with Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, to learn more about ETX101 as a potential disease-modifying therapy for DS and the company’s focus on pediatric neurologic disorders. He also discussed Encoded’s pipeline of therapies for other disorders.

REFERENCE
Hood V. Natural history study of children with Dravet Syndrome begins. March 19, 2021. Accessed August 10, 2021. https://www.dravetfoundation.org/natural-history-study-of-children-with-dravet-syndrome-begins/

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.